Abstract Number: 589 • 2016 ACR/ARHP Annual Meeting
Netosis-Derived Products Might Have Diagnostic Potential for Disease Activity, Atherosclerosis and Analysis of Therapeutic Effectiveness in Rheumatoid Arthritis Patients
Background/Purpose: Neutrophil extracellular traps (NETs) have recently been implicated in vascular damage and atherothrombosis. Extruded DNA fibers containing multiple proinflammatory and thrombotic molecules induce the…Abstract Number: 590 • 2016 ACR/ARHP Annual Meeting
Microvesicles in the Lungs of Early Rheumatoid Arthritis
Background/Purpose: Structural changes, increased tissue citrullination and signs of local inflammation are present in the pulmonary compartment of early seropositive RA and seropositive individuals at…Abstract Number: 591 • 2016 ACR/ARHP Annual Meeting
Patient-Reported Outcomes for Etanercept Therapy in Adult Patients with Moderate to Severe Rheumatoid Arthritis Who Failed Adalimumab Treatment
Background/Purpose: When a tumor necrosis factor inhibitor (TNFi) fails in a patient with moderate to severe rheumatoid arthritis (RA), new American College of Rheumatology (ACR)…Abstract Number: 592 • 2016 ACR/ARHP Annual Meeting
Impact of Adherence to Tumor Necrosis Factor Inhibitors on Radiographic Outcomes in US Veterans with Rheumatoid Arthritis
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are effective therapy for rheumatoid arthritis (RA) and have been shown to reduce progression of joint structural damage…Abstract Number: 593 • 2016 ACR/ARHP Annual Meeting
Adalimumab (HUMIRA) Halts Radiographic Progression and Reduces Disease Activity in Patients with a Poor Initial Response to Methotrexate
Background/Purpose: In patients (pts) with early rheumatoid arthritis (RA), conventional synthetic DMARDs (csDMARDs), preferably methotrexate (MTX), are recommended as first line therapy.1,2 For pts who…Abstract Number: 594 • 2016 ACR/ARHP Annual Meeting
Maintenance of Improvements in Patients’ Physical Function, Workplace and Household Productivity, and Reduction in Caregiver Burden with 2 Years of Certolizumab Pegol Treatment in DMARD-Naive, Early RA Patients with Severe Progressive Disease
Background/Purpose: Rheumatoid arthritis (RA) is associated with loss of physical function, work disability, and decreased quality of life. Early treatment with certolizumab pegol (CZP) in…Abstract Number: 595 • 2016 ACR/ARHP Annual Meeting
Cinical Responses and Improvements in Patient-Reported Outcomes Are Associated with Increased Productivity in the Workplace and at Home in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol
Background/Purpose: Rheumatoid arthritis (RA) is associated with work disability, loss of productivity and reduced quality of life. In established and early RA, compared with MTX…Abstract Number: 596 • 2016 ACR/ARHP Annual Meeting
Association Between Plasma Certolizumab Pegol Concentration and Improvement in Disease Activity in Rheumatoid Arthritis and Crohn’s Disease
Background/Purpose: Anti-TNFs neutralize the TNF-mediated component of inflammatory diseases such as rheumatoid arthritis (RA) and Crohn’s disease (CD) to reduce disease activity. In this study,…Abstract Number: 597 • 2016 ACR/ARHP Annual Meeting
Comparative Effectiveness of Different Anti-TNF Drugs As First Biological DMARD in RA: Results from the Nationwide Swedish Register 2010-2015
Background/Purpose: Although evidence from randomized trials suggest similar efficacy and safety on a group level for the different anti-TNF drugs available for the treatment of…Abstract Number: 598 • 2016 ACR/ARHP Annual Meeting
An Assessment of the Correlation Between Gender and Anticipated Drug Retention to TNF Inhibitors: A Meta-Regression Analysis
Background/Purpose: It is generally believed that a wide variety of patient-specific factors, and in particular gender, are likely to influence the response and tolerability of…Abstract Number: 599 • 2016 ACR/ARHP Annual Meeting
Real World United States-Based Clinical Experience with Prior Biologic Use Among First Time Golimumab Intravenous and Infliximab Treated Rheumatoid Arthritis Patients
Background/Purpose: AWARE (Comparative and Pragmatic Study of Golimumab IV Versus Infliximab in Rheumatoid Arthritis) is a Phase 4 comparator study designed to provide a real-world…Abstract Number: 600 • 2016 ACR/ARHP Annual Meeting
Disease Activity Trends after Dose Escalation of Infliximab (Remicade) – Results from United States Consortium of Rheumatology Researchers of North America Registry
Background/Purpose: Dose escalation is a common strategy for patients (pts) on infliximab (IFX). This study examined the trend in disease activity across dose escalations to…Abstract Number: 601 • 2016 ACR/ARHP Annual Meeting
Differing Contribution of Methotrexate Polyglutamation to Infliximab and Adalimumab Exposure As Compared to Etanercept
Background/Purpose: Methotrexate (MTX) is known to improve exposure and clinical outcome to anti-tumor necrosis factor (TNF) therapy. While the precise mechanism of action for the…Abstract Number: 602 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Switching Between Certolizumab Pegol and Adalimumab after Primary Anti-TNF Treatment Failure: 2-Year Results from a Randomized, Investigator-Blind, Superiority Head-to-Head Study
Background/Purpose: EULAR, ACR and treat-to-target guidelines recommend switching treatment in inadequate responders (IRs) to alternative therapy by Week (Wk) 12.1-3 Although any biological (b)DMARD can…Abstract Number: 603 • 2016 ACR/ARHP Annual Meeting
Additional Efficacy Results of SB4 (Etanercept Biosimilar) up to Week 100: Comparison Between Continuing SB4 and Switching from Reference Etanercept (Enbrel®) to SB4
Background/Purpose: SB4 is approved by the European Medicines Agency as a biosimilar of the reference etanercept (ETN). Long term safety and efficacy of SB4 up…
ACR Meeting Abstracts